MMA FREE Webinar Series - Coming to terms with death and dying through psychedelic-assisted therapies
Don’t miss out - Get your tickets early!
Join this FREE, 75-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.
Join this FREE WEBINAR presented by Spencer Hawkswell (Canada).
TheraPsil, a Canadian non-profit advocacy group, has made rapid and tangible progress in the fight for legal access to psilocybin-assisted psychotherapy for patients in medical need over the past 2 years. Spencer Hawkswell, CEO, will discuss precedent-setting wins and the ongoing challenges patients and healthcare professionals face, touching on advocacy, public education, training healthcare professionals and research, and discuss the future of this treatment option for patients facing end-of-life distress, substance use disorders, PTSD and other health conditions.
Topic: Coming to terms with death and dying through psychedelic-assisted therapies
Date: Wednesday 4 May 2022
Time: 12:55pm for 1:00pm start – 2:15pm (incl Q&A) (AEST)
The presentation WILL BEGIN AT 1:00pm.
Location: Online. A link will be emailed to you with the viewing details
Don’t miss out - Get your tickets early!
More about medicinal psychedelic treatments:
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments
for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many
more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent
clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and
self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the
availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive
clinical outcomes in large trials that are currently underway.
More about the presenters
Spencer Hawkswell (Canada)
Chief Executive Officer at TheraPsil
Spencer was first introduced to healing psychological trauma with altered states of consciousness and therapeutic psychedelics from reading the work of Terrence McKenna, Rick Strassman, and Carl Jung and believes that these methods need to be treated seriously by governments and institutions. Spencer believes that responsible drug policy requires effective organization and leadership and is dedicated to bringing together the experts and advocates, to facilitate change that results in increased access to compassionate care, harm reduction, and treatment options for those in need. Psilocybin-assisted psychotherapy is a reasonable treatment option for palliative patients in end-of-life distress and is where we need to begin.
Support psychedelic research and therapy development
By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of
psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your
Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.
Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.